Online citations, reference lists, and bibliographies.
← Back to Search

Nanomedicines For Treatment Of Viral Diseases.

Rujuta Mehendale, M. Joshi, V. Patravale
Published 2013 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Viral diseases affect millions of people worldwide, with a high impact on human health and socioeconomic development. More than 40 million people are affected with human immunodeficiency virus (HIV) alone. This review discusses the various nanocarriers (e.g., liposomes, solid lipid nanoparticles, polymeric nanoparticles, inorganic nanoparticles, etc.) based on approaches that have been applied in the literature and in the clinic to combat the different challenges faced by the antiviral therapy. The recent developments in smart delivery technologies (e.g., immunoliposomes) targeting delivery to the lectin receptors and cell-penetrating peptides for site-specific delivery of antiviral agents at the viral reservoirs are also been discussed.
This paper references
10.1016/j.ijpharm.2010.04.027
Dendrimer toxicity: Let's meet the challenge.
K. Jain (2010)
10.1016/j.addr.2009.11.022
Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS.
L. D. du Toit (2010)
10.1002/cbic.200500203
Dendritic Catanionic Assemblies: In vitro Anti‐HIV Activity of Phosphorus‐Containing Dendrimers Bearing Galβ1cer Analogues
M. Blanzat (2005)
10.1097/00006982-198707040-00005
INTRAVITREAL INJECTION OF LIPOSOME‐ENCAPSULATED GANCICLOVIR IN A RABBIT MODEL
G. Peyman (1987)
SLN as a topical delivery system for Artemisia arborescens essential oil: In vitro antiviral activity and skin permeation study
F. Lai (2007)
10.1002/smll.200902384
Inhibition of HSV-1 attachment, entry, and cell-to-cell spread by functionalized multivalent gold nanoparticles.
Dana Baram-Pinto (2010)
10.1016/J.VIROL.2006.08.012
Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages.
Huanyu Dou (2007)
10.1016/j.ijpharm.2011.06.037
Transport of saquinavir across human brain-microvascular endothelial cells by poly(lactide-co-glycolide) nanoparticles with surface poly-(γ-glutamic acid).
Y. Kuo (2011)
10.1371/journal.pone.0012309
Structure Activity Relationship of Dendrimer Microbicides with Dual Action Antiviral Activity
D. Tyssen (2010)
10.1211/0022357023691
Nanosuspensions: a promising drug delivery strategy
V. Patravale (2004)
10.1080/10611860600965914
Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro
T. Dutta (2007)
10.1016/0005-2736(94)90219-4
Liposome targeting to human immunodeficiency virus type 1-infected cells via recombinant soluble CD4 and CD4 immunoadhesin (CD4-IgG).
D. Flasher (1994)
10.2174/1381612003400704
Novel anti-RSV dianionic dendrimer-like compounds: design, synthesis and biological evaluation.
A. Gazumyan (2000)
10.1080/10611860600942178
Recent advances in delivery systems for anti-HIV1 therapy
J. M. Lanao (2007)
10.1186/1471-2334-9-198
Combination antiretroviral drugs in PLGA nanoparticle for HIV-1
C. Destache (2009)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1016/j.addr.2009.11.020
Nanotechnology applications for improved delivery of antiretroviral drugs to the brain.
H. L. Wong (2010)
10.1016/j.bmc.2009.06.035
Syntheses and biological evaluations of carbosilane dendrimers uniformly functionalized with sialyl alpha(2-->3) lactose moieties as inhibitors for human influenza viruses.
H. Oka (2009)
Silver nanoparticles inhibit hepatitis B virus replication. Antivir Ther
L. Lu (2008)
10.1007/s11095-008-9765-2
Targeted Delivery of PSC-RANTES for HIV-1 Prevention using Biodegradable Nanoparticles
A. S. Ham (2008)
10.1007/s11095-008-9615-2
Solid Lipid Nanoparticles Enhance the Delivery of the HIV Protease Inhibitor, Atazanavir, by a Human Brain Endothelial Cell Line
N. Chattopadhyay (2008)
10.1039/c1cc12981c
Multivalent glyconanoparticles with enhanced affinity to the anti-viral lectin Cyanovirin-N.
Xuxu Wang (2011)
10.1016/S0378-5173(96)04782-5
Solid lipid nanoparticles as drug carriers. I. Incorporation and retention of the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate
H. Heiati (1997)
10.1002/JPS.21020
pH-dependent interactions of indinavir and lipids in nanoparticles and their ability to entrap a solute.
Sung-Up Choi (2008)
10.1080/10611860802475688
Lymphatic targeting of zidovudine using surface-engineered liposomes
C. D. Kaur (2008)
10.1016/j.ijpharm.2008.08.050
Entrapment and release of saquinavir using novel cationic solid lipid nanoparticles.
Y. Kuo (2009)
10.1016/J.EJPS.2007.08.005
Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles.
O. Borges (2007)
10.1016/j.addr.2009.11.019
Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs.
P. Sharma (2010)
10.1016/J.ANTIVIRAL.2005.08.004
Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses.
Edwin Gong (2005)
10.1039/b901839p
Biomedical applications of dendrimers: a tutorial.
Meredith A. Mintzer (2011)
10.1016/j.ejpb.2008.05.008
Lipid nanoparticles as vehicles for topical psoralen delivery: solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC).
Jia-You Fang (2008)
10.1016/j.antiviral.2009.08.003
Sustained and specific in vitro inhibition of HIV-1 replication by a protease inhibitor encapsulated in gp120-targeted liposomes.
Reginald Clayton (2009)
10.1016/j.jconrel.2010.11.019
Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.
Ari S. Nowacek (2011)
10.1128/AAC.47.12.3784-3788.2003
Evaluations of Unformulated and Formulated Dendrimer-Based Microbicide Candidates in Mouse and Guinea Pig Models of Genital Herpes
D. Bernstein (2003)
[Treatment of recurrent condyloma acuminatum with solid lipid nanoparticle gel containing podophyllotoxin: a randomized double-blinded, controlled clinical trial].
Fang-ming Xie (2007)
10.1016/S0047-6374(96)01809-X
Summary of a clinical trial with liposome-adjuvanted influenza A virus vaccine in elderly adults
D. Powers (1997)
10.2217/nnm.09.71
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.
Ari S. Nowacek (2009)
10.1016/0166-3542(85)90050-6
The potential use of liposome-mediated antiviral therapy
W. Koff (1985)
10.1211/jpp.60.6.0001
Tumour and dendrimers: a review on drug delivery aspects
A. Agarwal (2008)
10.4049/jimmunol.0900274
Macrophage Delivery of Nanoformulated Antiretroviral Drug to the Brain in a Murine Model of NeuroAIDS1
Huanyu Dou (2009)
10.2478/v10007-007-0045-1
Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: In vitro and in vivo evaluation
A. Kaur (2008)
10.1038/nrd1632
Recent advances with liposomes as pharmaceutical carriers
V. Torchilin (2005)
10.1038/mt.2011.207
Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.
J. Zhou (2011)
10.1371/journal.pone.0002954
Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine
P. Makidon (2008)
10.1016/S0378-5173(98)00236-1
Solid lipid nanoparticles as drug carriers: II. Plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3′-azido-3′-deoxythymidine palmitate in mice
H. Heiati (1998)
10.2147/IJN.S7681
Progress in antiretroviral drug delivery using nanotechnology
R. Mallipeddi (2010)
10.3109/10717541003706257
Preparation and characterization of niosomes containing ribavirin for liver targeting
F. Hashim (2010)
The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes.
A. Chonn (1991)
10.3851/IMP1684
Nanoparticulate Delivery Systems for Antiviral Drugs
D. Lembo (2010)
10.1186/1477-3155-8-19
Interaction of silver nanoparticles with Tacaribe virus
Janice L. Speshock (2010)
10.1016/j.colsurfb.2011.07.060
Solid lipid nanoparticles comprising internal Compritol 888 ATO, tripalmitin and cacao butter for encapsulating and releasing stavudine, delavirdine and saquinavir.
Y. Kuo (2011)
10.1016/J.CCT.2006.11.001
Ethical issues in clinical trials involving nanomedicine.
D. Resnik (2007)
10.1080/10611860600612953
Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles
V. Mishra (2006)
10.1021/bc900215b
Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate.
Dana Baram-Pinto (2009)
10.1093/JAC/DKH399
Glycodendritic structures: promising new antiviral drugs.
Javier Rojo (2004)
10.1002/JPS.2600841202
Pharmacokinetics of a novel HIV-1 protease inhibitor incorporated into biodegradable or enteric nanoparticles following intravenous and oral administration to mice.
J. C. Leroux (1995)
AIDS Res Hum Retroviruses
A. Kamarulzaman (2006)
10.1016/j.addr.2009.11.008
Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications.
B. Fadeel (2010)
10.1038/nrd1494
Nanosuspensions in drug delivery
Barrett E. Rabinow (2004)
10.1086/344316
Prevention of influenza pneumonitis by sialic Acid-conjugated dendritic polymers.
Jeffrey J. Landers (2002)
10.1016/J.IJPHARM.2007.03.012
Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoacrylate, methylmethacrylate-sulfopropylmethacrylate, and solid lipid nanoparticles.
Y. Kuo (2007)
10.1016/j.ejps.2008.04.002
Targeting of efavirenz loaded tuftsin conjugated poly(propyleneimine) dendrimers to HIV infected macrophages in vitro.
T. Dutta (2008)
10.1016/j.ijantimicag.2008.12.004
Characterisation of copper oxide nanoparticles for antimicrobial applications.
G. Ren (2009)
10.1007/s11671-008-9128-2
A Preliminary Assessment of Silver Nanoparticle Inhibition of Monkeypox Virus Plaque Formation
J. Rogers (2008)
10.1631/jzus.B0820047
Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy
Zhang Xing-guo (2008)
Nevirapine nanosuspensions for HIV reservoir targeting.
R. Shegokar (2011)
10.1039/B510984A
Silver nanoparticles fabricated in Hepes buffer exhibit cytoprotective activities toward HIV-1 infected cells.
R. W. Sun (2005)
VivaGel™ (SPL7013 Gel): A candidate dendrimer – microbicide for the prevention of HIV and HSV infection
R. Rupp (2007)
10.1124/MOL.58.5.1100
Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
M. Witvrouw (2000)
10.1016/S1381-5148(00)00038-9
A review of chitin and chitosan applications
M. Kumar (2000)
10.1089/AID.2010.0295
Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neurons.
K. Borgmann (2011)
10.1073/pnas.1009445107
Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells
Stephanie Pollock (2010)
10.1016/S0923-2494(92)80167-J
Stimulation of Kupffer cell tumoricidal activity by liposomal muramyl dipeptides.
N. Phillips (1992)
10.3109/03639049209043684
Uptake capacity and adsorption isotherms of doxorubicin on polymeric nanoparticles: effect of methods of preparation
N. Bapat (1992)
10.1023/A:1016085108889
Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
M. P. Desai (2004)
10.1016/J.CARBPOL.2007.12.012
Synthesis and characterization of cross-linked malonylchitosan microspheres for controlled release of acyclovir
H. K. Stulzer (2008)
10.1016/S0169-409X(01)00149-1
Exploiting M cells for drug and vaccine delivery.
M. A. Clark (2001)
10.1128/AAC.40.6.1467
Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro.
A. Bender (1996)
10.1128/AAC.44.9.2471-2474.2000
Dendrimers, a New Class of Candidate Topical Microbicides with Activity against Herpes Simplex Virus Infection
N. Bourne (2000)
10.1016/S0923-2516(07)80025-2
Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles.
A. Bender (1994)
10.1016/j.vetmic.2012.05.035
Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
Ho-Jin Moon (2012)
10.1016/S0168-3659(00)00272-8
Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional state.
F. De Jaeghere (2000)
10.1007/s11095-011-0633-0
Sustained Cytoplasmic Delivery and Anti-viral Effect of PLGA Nanoparticles Carrying a Nucleic Acid-Hydrolyzing Monoclonal Antibody
Y. K. Joung (2011)
10.1016/S0378-5173(03)00408-3
Ultrasonication of chitosan and chitosan nanoparticles.
E. S. Tang (2003)
10.1371/journal.pone.0023388
Curcumin-Loaded Apotransferrin Nanoparticles Provide Efficient Cellular Uptake and Effectively Inhibit HIV-1 Replication In Vitro
Upendhar Gandapu (2011)
10.1002/wnan.1157
Recent advances in stealth coating of nanoparticle drug delivery systems.
Z. Amoozgar (2012)
10.1186/1477-3155-3-6
Interaction of silver nanoparticles with HIV-1
J. L. Elechiguerra (2005)
10.1016/J.IJPHARM.2007.09.020
Electromagnetic interference in the permeability of saquinavir across the blood-brain barrier using nanoparticulate carriers.
Y. Kuo (2008)
10.1016/j.ejpb.2011.01.020
A new approach for the evaluation of niosomes as effective transdermal drug delivery systems.
R. Muzzalupo (2011)
10.1021/BC980099N
Inhibition of viral adhesion and infection by sialic-acid-conjugated dendritic polymers.
J. Reuter (1999)
10.1016/J.IJPHARM.2006.07.044
Effect of nanoparticulate polybutylcyanoacrylate and methylmethacrylate-sulfopropylmethacrylate on the permeability of zidovudine and lamivudine across the in vitro blood-brain barrier.
Y. Kuo (2006)
10.1016/j.nano.2010.10.012
In vitro protein adsorption studies on nevirapine nanosuspensions for HIV/AIDS chemotherapy.
R. Shegokar (2011)
10.1023/A:1015852732512
Phagocytosis of Nanoparticles by Human Immunodeficiency Virus (HlV)-Infected Macrophages: A Possibility for Antiviral Drug Targeting
V. Schaefer (2004)
10.1016/J.IJPHARM.2007.06.016
Improved oral bioavailability and brain transport of Saquinavir upon administration in novel nanoemulsion formulations.
Tushar K Vyas (2008)
10.2217/17435889.1.3.297
Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential
M. Immordino (2006)
10.1080/10717540802321776
Polymeric Nanoparticles for Enhancing Antiretroviral Drug Therapy
T. Govender (2008)
10.1208/s12248-008-9039-2
Mucoadhesive Microspheres for Gastroretentive Delivery of Acyclovir: In Vitro and In Vivo Evaluation
S. Dhaliwal (2008)
10.1016/S1359-0286(02)00117-1
Biodegradable nanoparticles for drug delivery and targeting
M. Hans (2002)
10.1093/jac/dkq318
Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in mice.
C. Destache (2010)
10.1021/jm701494b
Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein.
J. Rollinger (2008)
10.1021/MP050023Q
Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention.
T. D. Mccarthy (2005)
10.1016/j.ijpharm.2011.09.041
Surface modified nevirapine nanosuspensions for viral reservoir targeting: In vitro and in vivo evaluation.
R. Shegokar (2011)
10.1016/j.antiviral.2011.03.186
Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
S. Telwatte (2011)
10.1007/s11095-006-9101-7
Intracellular Delivery of Saquinavir in Biodegradable Polymeric Nanoparticles for HIV/AIDS
Lipa K Shah (2006)
10.1016/j.colsurfb.2011.02.023
Bacteria and bacteriophage inactivation by silver and zinc oxide nanoparticles.
Jia You (2011)
10.1016/S1045-1870(96)81012-0
Pulmonary delivery of antiviral drugs in liposome aerosols
B. Gilbert (1996)
10.1016/S0939-6411(97)00078-7
Body distribution of azidothymidine bound to nanoparticles after oral administration
R. Löbenberg (1997)
10.1016/J.JFLUCHEM.2007.05.023
Preparation of fluoroalkyl end-capped cooligomers/silica nanoparticles: A new approach to fluorinated nanoparticle inhibitors of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus (SIVmac)
H. Sawada (2007)
10.1097/00004424-200204000-00005
Biodistribution of a 153Gd-Folate Dendrimer, Generation = 4, in Mice With Folate-Receptor Positive and Negative Ovarian Tumor Xenografts
S. Konda (2002)
10.1517/17425240903338055
Nanoparticle-based vaginal drug delivery systems for HIV prevention
R. Mallipeddi (2010)
10.1016/S0166-3542(02)00054-2
Evidence of dual sites of action of dendrimers: SPL-2999 inhibits both virus entry and late stages of herpes simplex virus replication.
Y. Gong (2002)
Sustained release of acyclovir from nano-liposomes and nano-niosomes: An in vitro study
B. Mukherjee (2007)
10.1016/0168-3659(94)90039-6
Liposomes and niosomes as topical drug carriers: dermal and transdermal drug delivery
H. Schreier (1994)
10.1007/s11481-010-9198-7
Nanoformulated Antiretroviral Drug Combinations Extend Drug Release and Antiretroviral Responses in HIV-1-Infected Macrophages: Implications for NeuroAIDS Therapeutics
Ari S. Nowacek (2010)
10.1016/0166-3542(92)90058-D
Drug targeting systems for antiviral agents: options and limitations.
D. Meijer (1992)
10.1007/s11095-008-9800-3
Methods for the Preparation and Manufacture of Polymeric Nanoparticles
C. Vauthier (2008)
10.1016/J.SURVOPHTHAL.2004.12.006
Applications of liposomes in ophthalmology.
S. Ebrahim (2005)
10.1016/J.CARBPOL.2009.12.040
Preparation of poly(lactic acid)/chitosan nanoparticles for anti-HIV drug delivery applications
Ashish Dev (2010)
10.1007/s11095-007-9402-5
Peritoneal Macrophage Uptake, Pharmacokinetics and Biodistribution of Macrophage-Targeted PEG-fMLF (N-Formyl-Methionyl-Leucyl-Phenylalanine) Nanocarriers for Improving HIV Drug Delivery
L. Wan (2007)
10.1016/j.ejpb.2008.09.003
Lipid nanoparticles for parenteral delivery of actives.
Medha D. Joshi (2009)
10.1023/A:1011050209986
Targeting of 3′-Azido 3′-Deoxythymidine (AZT)-Loaded Poly(Isohexylcyanoacrylate) Nanospheres to the Gastrointestinal Mucosa and Associated Lymphoid Tissues
Assia Dembri (2004)
10.1006/BBRC.1996.1592
Targeting of liposomes to HIV-1-infected cells by peptides derived from the CD4 receptor.
V. Slepushkin (1996)
10.1211/jpp.58.5.0005
Stavudine‐loaded mannosylated liposomes: in‐vitro anti‐HIV‐I activity, tissue distribution and pharmacokinetics
M. Garg (2006)
10.1073/PNAS.85.18.6949
Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.
A. Gabizon (1988)
10.1016/J.NANO.2005.12.003
Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles.
C. Reis (2006)
10.1128/AAC.01529-09
Pharmacokinetics and Disposition of Rilpivirine (TMC278) Nanosuspension as a Long-Acting Injectable Antiretroviral Formulation
Gerben van 't Klooster (2010)
10.1021/LA010808C
Formation and Stability of Nano-Emulsions Prepared Using the Phase Inversion Temperature Method
P. Izquierdo (2002)
Formulation and evaluation of Acyclovir niosomes for ophthalmic use
Ahmed N. Allam (2011)
10.1111/j.1747-0285.2006.00454.x
Influence of Generation 2–5 of PAMAM Dendrimer on the Inhibition of Tat Peptide/ TAR RNA Binding in HIV‐1 Transcription
W. Wang (2006)
10.1023/A:1019854327540
Comparative Uptake Studies of Bioadhesive and Non-Bioadhesive Nanoparticles in Human Intestinal Cell Lines and Rats: The Effect of Mucus on Particle Adsorption and Transport
I. Behrens (2004)
10.1002/chem.200800402
Synthesis and relaxometric studies of a dendrimer-based pH-responsive MRI contrast agent.
M. Ali (2008)
10.1016/J.JVIROMET.2006.08.017
Binding kinetics, uptake and intracellular accumulation of F105, an anti-gp120 human IgG1kappa monoclonal antibody, in HIV-1 infected cells.
Reginald Clayton (2007)
10.1016/S0001-706X(03)00120-7
Inactivation of Ebola virus with a surfactant nanoemulsion.
A. Chepurnov (2003)
10.1016/j.nano.2007.11.004
Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery.
S. Jain (2008)
10.1016/S0169-409X(97)90003-X
Adv. Drug Delivery Rev.
F. Welt (1997)
10.1002/smll.201001349
Inhibition of influenza virus infection by multivalent sialic-acid-functionalized gold nanoparticles.
Ilona Papp (2010)
10.1211/jpp.61.12.0004
Chitosan‐tripolyphosphate nanoparticles as a possible skin drug delivery system for aciclovir with enhanced stability
A. Hasanovic (2009)
10.1016/j.bmc.2009.02.055
Comparing anti-HIV, antibacterial, antifungal, micellar, and cytotoxic properties of tricarboxylato dendritic amphiphiles.
Richard V. Macri (2009)
10.1016/j.jconrel.2008.02.007
Design and production of nanoparticles formulated from nano-emulsion templates-a review.
N. Anton (2008)
10.1211/jpp.61.08.0002
Dendrimers as therapeutic agents: a systematic review
V. Gajbhiye (2009)
10.1016/j.ijpharm.2011.11.038
Optimisation of multiple W/O/W nanoemulsions for dermal delivery of aciclovir.
J. Schwarz (2012)
Silver nanoparticles inhibit hepatitis B virus replication.
L. Lu (2008)
Inhibition of herpes simplex virus replication in the mouse cornea by drug containing immunoliposomes.
S. Norley (1987)
10.1186/1477-3155-8-1
Mode of antiviral action of silver nanoparticles against HIV-1
H. H. Lara (2010)
10.1111/J.1740-8261.2000.TB01462.X
The role of liposomes in drug delivery and diagnostic imaging: a review.
M. L. Matteucci (2000)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1111/j.1467-2494.1979.tb00224.x
Dispersions of lamellar phases of non‐ionic lipids in cosmetic products
R. Handjani-Vila (1979)
10.1016/j.jconrel.2011.02.023
Cell derived liposomes expressing CCR5 as a new targeted drug-delivery system for HIV infected cells.
Tomer Bronshtein (2011)
10.1097/00006123-199810000-00090
Improving Drug Delivery to Intracerebral Tumor and Surrounding Brain in a Rodent Model: A Comparison of Osmotic versus Bradykinin Modification of the Blood-Brain and/or Blood-Tumor Barriers
Robert A. Kroll (1998)
10.1016/j.addr.2009.11.018
Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting.
U. Gupta (2010)
10.3390/molecules16108894
Silver Nanoparticles as Potential Antiviral Agents
Stefania Galdiero (2011)
10.1002/wnan.118
Nanotechnology and HIV: potential applications for treatment and prevention.
P. Kim (2010)
10.3390/biom2020187
Cell Penetrating Peptides in the Delivery of Biopharmaceuticals
Were LL Munyendo (2012)
10.1182/BLOOD-2006-03-012534
Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery.
Huanyu Dou (2006)
10.1016/S0168-3659(97)00105-3
Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats.
R. Löbenberg (1998)
10.1016/j.jconrel.2007.12.018
Potential of solid lipid nanoparticles in brain targeting.
I. P. Kaur (2008)
10.3892/IJO.17.2.309
Targeted delivery of anticancer drugs with intravenously administered magnetic liposomes in osteosarcoma-bearing hamsters.
T. Kubo (2000)
10.1182/BLOOD.V79.5.1137.1137
Liposomal encapsulation of azidothymidine results in decreased hematopoietic toxicity and enhanced activity against murine acquired immunodeficiency syndrome.
N. Phillips (1992)
10.1517/17425247.2011.543673
Potential of polymeric nanoparticles in AIDS treatment and prevention
N. Khalil (2011)
10.2174/157016210791330356
Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles.
S. Mahajan (2010)
10.1089/AID.2005.21.207
SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques.
Y. Jiang (2005)
Key issues in non-viral gene delivery: Adv Drug Deliv Rev
C. Pouton (1998)
10.1016/S0378-5173(98)00169-0
Non-ionic surfactant based vesicles (niosomes) in drug delivery
I. Uchegbu (1998)
10.1177/095632020001100104
Prevention of Murine Influenza a Virus Pneumonitis by Surfactant Nano-Emulsions
B. Donovan (2000)
10.1016/J.JCONREL.2004.08.010
Recent advances on chitosan-based micro- and nanoparticles in drug delivery.
S. Agnihotri (2004)
10.1128/AAC.48.10.3834-3844.2004
In Vitro Comparison of Topical Microbicides for Prevention of Human Immunodeficiency Virus Type 1 Transmission
C. Dezzutti (2004)
10.1016/J.CARBPOL.2006.07.001
Synthesis and characterization of semi-interpenetrating polymer network microspheres of acrylamide grafted dextran and chitosan for controlled release of acyclovir
A. P. Rokhade (2007)
10.1016/j.vaccine.2011.09.033
Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
N. Gupta (2011)
10.1016/J.CES.2005.06.019
Inorganic nanoparticles as carriers for efficient cellular delivery
Z. P. Xu (2006)
10.1016/J.BBAGEN.2006.12.007
Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer.
T. Dutta (2007)
10.1016/S0169-409X(98)00048-9
Key issues in non-viral gene delivery.
C. Pouton (2001)



This paper is referenced by
Synthesis of zinc oxide nanoparticles and evaluated its activity against bacterial isolates
S. Albukhaty (2020)
10.1016/j.actatropica.2017.02.019
Nanopharmaceuticals as a solution to neglected diseases: Is it possible?
G. Islan (2017)
10.1166/JBN.2015.1942
Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.
A. Date (2015)
10.1021/acsami.9b06365
Application of Virus Targeting Nanocarrier Drug Delivery System in Virus-Induced Central Nervous System Disease Treatment.
S. Zhu (2019)
NANOBIOTECHNOLOGY: A POTENTIAL TOOL FOR BIOMEDICS
Vikas Shrivastava (2015)
10.1080/17425247.2017.1360863
Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections
D. Lembo (2018)
Preparation and Characterization of Gelatin-Stavudine Conjugated Liposomal Nanoparticles for Better Delivery in Case Of HIV
Ankita Boxi (2015)
10.1038/nrd4333
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
V. Torchilin (2014)
10.1097/COH.0000000000000151
Towards an HIV cure based on targeted killing of infected cells: different approaches against acute versus chronic infection
B. Dey (2015)
10.1016/j.colsurfb.2014.03.037
Preparation, characterization and in vitro antiviral activity evaluation of foscarnet-chitosan nanoparticles.
E. Russo (2014)
10.1002/mabi.201500094
Shell Cross-Linked Polymeric Micelles as Camptothecin Nanocarriers for Anti-HCV Therapy.
I. Jiménez-Pardo (2015)
10.1016/J.EURPOLYMJ.2017.03.012
Nanostructures based on ammonium-terminated amphiphilic Janus dendrimers as camptothecin carriers with antiviral activity
A. Lancelot (2017)
10.18502/pbr.v5i4.2392
Applying Nanoparticles in the Treatment of Viral Infections and Toxicological Considerations
Zohreh Fasili (2020)
10.4155/ppa.13.79
Pharmaceutical and biomedical applications of lipid-based nanocarriers.
C. Carbone (2014)
10.1016/j.jconrel.2016.01.008
Current applications of nanoparticles in infectious diseases.
H. Zazo (2016)
10.1111/bcp.12403
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future.
A. Tseng (2015)
10.1007/s12272-018-1008-4
Recent progress in dendrimer-based nanomedicine development
Yejin Kim (2018)
10.1177/2049936117713593
The role of nanotechnology in the treatment of viral infections
Lavanya Singh (2017)
10.1016/j.biomaterials.2015.11.008
DNA-AuNP networks on cell membranes as a protective barrier to inhibit viral attachment, entry and budding
C. Li (2016)
Semantic Scholar Logo Some data provided by SemanticScholar